The information is already in the tissue.
Every cancer patient already has a pathology slide. Almost none get the molecular answer hidden inside it. Imagenomix predicts cancer genetics directly from that slide with AI, first to predict, publish, and patent mutation detection from H&E, and we are turning a closed market open.
NYU Langone spin-off · technology discovered 2017 · patented 2022
The opportunity
A market defined by who it leaves out.
Molecular testing guides precision oncology, but it is slow, expensive, and tissue-hungry, so most patients never get it. Imagenomix does not compete for the slice that already gets sequenced. It expands the market to the slides that never reach a sequencer at all.
Each unfilled bar is a patient who never gets a genomic answer. That bar is the market.
An AI prescreen rules driver mutations in or out before that spend is committed, lowering cost per patient from roughly $6,000 to about $200, the wedge into both clinical and biopharma budgets.
Sources: Imagenomix analysis; published molecular testing rates in US and global oncology. Figures are approximate and directional.
Why now, why us
A moat with a date on it.
Foundation-model labs can predict from images. They cannot un-publish our 2018 science or un-grant our 2022 patent. The defensibility is sequenced into the timeline.
First to predict cancer driver mutations directly from H&E slides with deep learning, the founding science, 2018.
First to publish that result in peer review, among the most-cited works in computational pathology.
First and only to patent it, US 11,367,180, image-to-mutation prediction with spatial mapping.
One platform, four products, more coming
IGX Predict™ is the platform; Pulmogene, BLISS, NeuroInsight, and DermPredict run within it. New cancer types extend the moat without rebuilding it.
Zero new infrastructure to adopt
Runs on the H&E slide already produced for diagnosis. No new tissue, no new equipment, no workflow to rip and replace, which collapses the cost of distribution.
Traction
From a lab question to a live platform.
The milestones that turned a research discovery into a commercial company.
Technology discovered at NYU Langone Health
The core method behind IGX Predict™ is discovered at the Perlmutter Cancer Center: predict mutation signal directly from a stained slide, no sequencing required.
First to predict and publish from H&E slides
NYU faculty are first to predict cancer driver mutations directly from H&E slides with deep learning (Coudray et al., Nature Medicine), the founding peer-reviewed science.
Proven and validated at scale
The approach becomes among the most-cited in computational pathology and is independently validated across mutation targets and cohorts.
Patented: US Patent 11,367,180
The foundational patent on image-to-mutation prediction with spatial heatmap mapping is granted, making IGX Predict™ the only patent-protected platform of its kind.
Commercialized as an NYU Langone spin-off
Imagenomix spins out to bring the science to labs, pharma, and biobanks.
Platform live globally
Four products across four cancer types are live on IGX Predict™, with Proscia integration and biopharma engagements underway.
Request the data room.
If you invest where deep science meets a wide-open market, we would like to talk. Request access and we will follow up to confirm fit.
Prefer email? Reach investor relations through our contact page and select "Investors" as the topic.
This page is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. Any such offer is made only to qualified investors through definitive offering documents. Forward-looking statements involve risk and uncertainty. IGX Predict is for Research Use Only and is not cleared or approved for diagnostic or therapeutic use. Market and percentage figures are approximate and directional.